Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 192

The DOI matches its Crossref record.

Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia

Open access
Egbelakin, Akinbode, Ferguson, Michael J., MacGill, Emily A., Lehmann, Amalia S., Topletz, Ariel R., Quinney, Sara K., Li, Lang, McCammack, Kevin C., Hall, Stephen D., Renbarger, Jamie L.·2011·Pediatric Blood & Cancer

Abstract

Background: This study evaluates the relationship between cytochrome P450 (CYP) 3A5 genotype and vincristine‐induced peripheral neuropathy (VIPN) in children with precursor B cell acute lymphoblastic leukemia (preB ALL). We have shown in vitro that vincristine is metabolized significantly more efficiently by CYP3A5 than by CYP3A4. We also found that vincristine neurotoxicity is less common in African‐Americans (70% express CYP3A5) than in Caucasians. We test the hypothesis that CYP3A5 expressers experience less vincristine neuropathy than do CYP3A5 non‐expressers. Procedure: This study of pharmacogenetics of vincristine neuropathy in children with preB ALL was completed at Indiana University Simon Cancer Center. Whole blood for DNA extraction and genotyping was collected as well as plasma from a single time‐point for analysis of vincristine and primary metabolite (M1) concentrations. Vincristine neuropathy was captured via chart review and graded per the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. Results: Eighty‐nine percent of CYP3A5 expressers experienced neurotoxicity versus 100% of non‐expressers (P = 0.03). The proportion of treatment months with neurotoxicity was significantly different between the expressers and non‐expressers (16% vs. 27%,P = 0.0007). Limited pharmacokinetic data suggest different rates of vincristine metabolism between CYP3A5 genotype groups with higher primary metabolite (M1) plasma concentrations (P = 0.0004) and lower metabolic ratios ([vincristine]/[M1]) (P = 0.036) in the CYP3A5 expressers compared to the CYP3A5 non‐expressers. M1 concentration was also inversely related to severity of neuropathy (P = 0.0316). Conclusions: In children with preB ALL, CYP3A5 expressers experience less VIPN, produce more M1, and have lower metabolic ratios compared to CYP3A5 non‐expressers. Pediatr Blood Cancer 2011;56:361–367. © 2010 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/pbc.22845

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 192

Metadata

Authors
Egbelakin, A., Ferguson, M. J., MacGill, E. A., Lehmann, A. S., Topletz, A. R., Quinney, S. K., Li, L., McCammack, K. C., Hall, S. D., & Renbarger, J. L.
Venue
Pediatric Blood & Cancer
Publisher
Wiley
Published
2010-11-11
Volume
56
Issue
3
Pages
361-367
ISSN
  • 1545-5009 (ISSN-L)
  • 1545-5017
OpenAlex
W2131309128
Cited by
192
References
0
FWCI
8.63
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. https://app.cochat.ai/papers/10.1002/pbc.22845
The paper
Egbelakin, A., Ferguson, M. J., MacGill, E. A., Lehmann, A. S., Topletz, A. R., Quinney, S. K., Li, L., McCammack, K. C., Hall, S. D., & Renbarger, J. L. (2011). Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.22845

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.